Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization
54 Citations•2022•
JAMA Network Open
This systematic review and meta-analysis examines randomized clinical trial evidence for fluvoxamine to prevent hospitalization of patients with COVID-19 and concludes that the drug should be considered for use in combination with chemotherapy to treat central nervous system disorders.
Abstract
This systematic review and meta-analysis examines randomized clinical trial evidence for fluvoxamine to prevent hospitalization of patients with COVID-19.